Literature DB >> 15126158

Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy.

Salvatore Grisanti1, Olcay Tatar, Serap Canbek, Bart A Lafaut, Faik Gelisken, Werner Inhoffen, Peter Szurman, Sabin Aisenbrey, Jolanta Oficjalska-Mlynczak, Karl Ulrich Bartz-Schmidt.   

Abstract

PURPOSE: To evaluate the vascularization and proliferative activity in choroidal neovascular membranes due to age-related macular degeneration after verteporfin photodynamic therapy and submacular removal.
DESIGN: Interventional case series.
METHODS: In a retrospective review of seven patients who underwent removal of subfoveal classic choroidal neovascular membranes after treatment with photodynamic therapy 3 to 146 days earlier, membranes were stained for CD 34, CD 105, and Ki-67 and correlated with clinical pictures and fluorescein angiography.
RESULTS: Fluorescein angiography performed on the day of surgery disclosed nonperfusion of the treated area 3 days after photodynamic therapy, but perfusion and leakage were seen at greater post-photodynamic therapy intervals. Membranes excised 3 days after photodynamic therapy showed CD34 and CD105 positive, mostly occluded vessels. The endothelial cells appeared damaged. Ki-67 activity was low. In membranes excised 34 to 146 days after photodynamic therapy, all vessels appeared patent and were lined by healthy endothelial cells with strong expression of CD34 and CD105. Ki-67 expression was elevated after 34 days but decreased thereafter.
CONCLUSION: Photodynamic therapy did not cause a general or complete occlusion of vessels within the choroidal neovascular membranes, as suggested by fluorescein angiography 3 days postintervention, but the endothelial cells appeared to be severely damaged. Proliferative activity within these specimens was reduced. At longer intervals after photodynamic therapy, the fibrovascular tissue seemed to recover; perfusion, hyperfluorescence, and leakage of the choroidal neovascular membranes could be detected by fluorescein angiography. The clinical appearance showed a correlation with the immunohistologic characteristics of an increased proliferative activity and patent vascularization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126158     DOI: 10.1016/j.ajo.2003.12.049

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Which treatment is best for which AMD patient?

Authors:  P Kroll; C H Meyer
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

2.  Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes.

Authors:  Olcay Tatar; Kei Shinoda; Annemarie Adam; Tillmann Eckert; Claus Eckardt; Klaus Lucke; Christoph Deuter; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

3.  [Does acetylsalicylic acid have a negative influence on photodynamic therapy?].

Authors:  U Löw; J K Kohlhof; K W Ruprecht
Journal:  Ophthalmologe       Date:  2006-03       Impact factor: 1.059

Review 4.  Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Caroline Fenton; Caroline M Perry
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

5.  Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes.

Authors:  K Petermeier; O Tatar; W Inhoffen; M Völker; B A Lafaut; S Henke-Fahle; F Gelisken; F Ziemssen; S Bopp; K U Bartz-Schmidt; S Grisanti
Journal:  Br J Ophthalmol       Date:  2006-04-13       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.